share_log

DaVita | 8-K: Current report

DaVita | 8-K: Current report

德維特 | 8-K:重大事件
美股SEC公告 ·  2024/09/14 04:18

牛牛AI助理已提取核心訊息

DaVita announced the appointment of David P. Maughan as Chief Operating Officer of DaVita Kidney Care, effective September 15, 2024. Maughan, 47, will replace Michael D. Staffieri, who will transition to the role of Chief Operating Officer Emeritus. Maughan has been with DaVita since 2006, most recently serving as Senior Vice President, Kidney Care.In connection with this transition, DaVita entered into an employment agreement with Maughan. The agreement includes an annual base salary of $725,000, participation in the company's annual incentive plan with a 2024 target bonus opportunity of 100% of base salary, and participation in employee benefit plans and long-term incentive plans. The agreement also outlines severance benefits in case of termination without cause or resignation for good cause.Maughan's appointment comes after serving in various roles of increasing responsibility at DaVita, including oversight of national home and hospital services businesses, as well as key functions such as human resources, IT, marketing, and state government affairs. He holds an MBA from Harvard Business School and previously worked at Goldman Sachs in Finance.
DaVita announced the appointment of David P. Maughan as Chief Operating Officer of DaVita Kidney Care, effective September 15, 2024. Maughan, 47, will replace Michael D. Staffieri, who will transition to the role of Chief Operating Officer Emeritus. Maughan has been with DaVita since 2006, most recently serving as Senior Vice President, Kidney Care.In connection with this transition, DaVita entered into an employment agreement with Maughan. The agreement includes an annual base salary of $725,000, participation in the company's annual incentive plan with a 2024 target bonus opportunity of 100% of base salary, and participation in employee benefit plans and long-term incentive plans. The agreement also outlines severance benefits in case of termination without cause or resignation for good cause.Maughan's appointment comes after serving in various roles of increasing responsibility at DaVita, including oversight of national home and hospital services businesses, as well as key functions such as human resources, IT, marketing, and state government affairs. He holds an MBA from Harvard Business School and previously worked at Goldman Sachs in Finance.
德維特宣佈任命David P. Maughan爲德維特腎臟護理的首席運營官,任命將於2024年9月15日生效。47歲的Maughan將接替Michael D. Staffieri,後者將轉任首席運營官名譽職務。Maughan自2006年起加入德維特,最近擔任腎臟護理的高級副總裁。爲了配合這一過渡,德維特與Maughan簽訂了僱傭協議。該協議包括725,000美元的年基本工資,參與公司年度激勵計劃,2024年的目標獎金機會爲基本工資的100%,並參與員工福利計劃和長期激勵計劃。該協議還概述了在因無故解僱或因正當理由辭職時的遣散福利。Maughan的任命是在德維特擔任越來越多責任的多個職位後做出的,包括監督全國的家庭和醫院服務業務,以及人力資源、IT、市場營銷和州政府事務等關鍵職能。他擁有哈佛商學院的MBA學位,之前在高盛從事金融工作。
德維特宣佈任命David P. Maughan爲德維特腎臟護理的首席運營官,任命將於2024年9月15日生效。47歲的Maughan將接替Michael D. Staffieri,後者將轉任首席運營官名譽職務。Maughan自2006年起加入德維特,最近擔任腎臟護理的高級副總裁。爲了配合這一過渡,德維特與Maughan簽訂了僱傭協議。該協議包括725,000美元的年基本工資,參與公司年度激勵計劃,2024年的目標獎金機會爲基本工資的100%,並參與員工福利計劃和長期激勵計劃。該協議還概述了在因無故解僱或因正當理由辭職時的遣散福利。Maughan的任命是在德維特擔任越來越多責任的多個職位後做出的,包括監督全國的家庭和醫院服務業務,以及人力資源、IT、市場營銷和州政府事務等關鍵職能。他擁有哈佛商學院的MBA學位,之前在高盛從事金融工作。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。